Mentalisation-Based Treatment for Dual Diagnoses
- Conditions
- Current condition as of 10/12/2014: Borderline personality disorder with substance dependence (dependence on alcohol, amphetamines, cannabis, cocaine, hallucinogens, opioids, phencyclidine, sedatives/hypnotics/anxiolytics, or poly-substance – present or in remission) Previous condition: Borderline personality disorder with opiate dependence (present or in remission)Mental and Behavioural Disorders
- Registration Number
- ISRCTN98982683
- Lead Sponsor
- Stockholm County Council (Sweden)
- Brief Summary
2018 results in https://pubmed.ncbi.nlm.nih.gov/29402870/ (added 01/09/2020)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 46
Current inclusion criteria as of 10/12/2014:
Participant inclusion criteria
1. Aged 18 - 65 years, either sex
2. Provide written informed consent to participate in the study
3. Address and telephone number in Stockholm County where the patient can be reached
4. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for borderline personality disorder
5. Meet DSM-IV criteria for substance dependence (dependence on alcohol, amphetamines, cannabis, cocaine, hallucinogens, opioids, phencyclidine, sedatives/hypnotics/anxiolytics, or poly-substance – present or in remission)
6. Ongoing dependency care at a dependency care outpatient unit (for patients with opiate dependence, ongoing pharmacological treatment with buprenorphine or methadone for at least 3 months)
Previous inclusion criteria:
1. Aged 18 - 65 years, either sex
2. Provide written informed consent to participate in the study
3. Address and telephone number in Stockholm County where the patient can be reached
4. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for borderline personality disorder
5. Meet DSM-IV criteria for opiate dependence (present or in remission)
6. Ongoing pharmacological treatment with buprenorphine or methadone for at least 3 months
1. Meet DSM-IV criteria for schizophrenia, schizoaffective disorder or bipolar I disorder, (other psychotic or mood disorders do not constitute exclusion criteria)
2. Mental retardation or borderline intellectual functioning (intelligence quotient [IQ] less than 85)
3. Autistic disorder or Aspergers disorder
4. Psychopathy according to Psychopathy Checklist: Screening Version (PCL-SV)
5. Psychotherapy outside the research project, which is ongoing or terminated less than three months ago
Added 10/12/2014:
6. Not able to communicate in Swedish without help from an interpreter
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> The Borderline Personality Disorder Severity Index, 4th Edition (BPDSI-IV).<br><br> The main effect concerns change from baseline to termination of treatment (18 months). Intent-to-treat analysis by last observation carried forward will be used and the statistical analysis will be ANOVA with repeated measures.<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Timeline Follow Back and specimens of urine for use of opiates, alcohol and other drugs<br> 2. Beck's Suicidal Intent Scale (SIS)<br> 3. Deliberate Self-Harm Inventory (DSHI-9)<br> 4. Global Assessment of Functioning (GAF)<br> 5. Symptom Check List 90 (SCL-90)<br> 6. Inventory of Interpersonal Problems (IIP), short version<br> 7. Social Adjustment Scale - Self Report (SAS-SR)<br> 8. Retention in treatment<br> 9. Reflective Functioning Interview (for mediator analysis)<br><br> The measures are used at baseline and at 6-monthly intervals until the end of treatment. Follow up: 6 and 18-months after endpoint.<br><br> Long-term follow up from register data:<br> 10. Health economy (health care utilisation and work/income)<br> 11. Criminality<br> 12. Survival<br>